AtriCureATRC
ATRC
About: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Employees: 1,300
0
Funds holding %
of 7,202 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
626% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $145K
28% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 29
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
14% more capital invested
Capital invested by funds: $1.42B [Q4 2024] → $1.62B (+$202M) [Q1 2025]
2.16% more ownership
Funds ownership: 95.26% [Q4 2024] → 97.42% (+2.16%) [Q1 2025]
1% more funds holding
Funds holding: 211 [Q4 2024] → 213 (+2) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$44
29%
upside
Avg. target
$53
57%
upside
High target
$60
76%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
UBS Danielle Antalffy | 70%upside $58 | Buy Maintained | 30 Apr 2025 |
JMP Securities Daniel Stauder | 76%upside $60 | Market Outperform Reiterated | 30 Apr 2025 |
Needham Mike Matson | 29%upside $44 | Buy Maintained | 30 Apr 2025 |
Citizens Capital Markets Daniel Stauder | 76%upside $60 | Market Outperform Reiterated | 2 Apr 2025 |
Canaccord Genuity William Plovanic | 53%upside $52 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Based on 5 articles about ATRC published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
2 weeks ago
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.
Positive
Zacks Investment Research
2 weeks ago
AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Negative
Zacks Investment Research
2 weeks ago
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
Neutral
Business Wire
3 weeks ago
AtriCure Reports First Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As.
Neutral
Business Wire
1 month ago
AtriCure Announces First Use of the AtriClip PRO-Mini® Device
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System. The AtriClip PRO-Mini device received FDA 510K clearance earlier this year and is a testament to AtriCure's commitment.
Neutral
Business Wire
1 month ago
AtriCure to Announce First Quarter 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list.
Neutral
Business Wire
2 months ago
AtriCure to Host Analyst & Investor Day on March 26, 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa.
Positive
Zacks Investment Research
3 months ago
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
3 months ago
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Charts implemented using Lightweight Charts™